Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
1.430
-0.040 (-2.72%)
At close: Aug 12, 2025, 4:00 PM
1.410
-0.020 (-1.40%)
Pre-market: Aug 13, 2025, 5:16 AM EDT
Scinai Immunotherapeutics Employees
Scinai Immunotherapeutics had 31 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
31
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$21,226
Profits / Employee
n/a
Market Cap
1.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31 | 0 | - |
| Dec 31, 2023 | 31 | -2 | -6.06% |
| Dec 31, 2022 | 33 | 18 | 120.00% |
| Dec 31, 2021 | 15 | -6 | -28.57% |
| Dec 31, 2020 | 21 | -4 | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SCNI News
- 14 days ago - Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - PRNewsWire
- 2 months ago - Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - PRNewsWire
- 2 months ago - Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PRNewsWire
- 2 months ago - Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - PRNewsWire
- 3 months ago - Scinai Announces Annual Financial Results for 2024 - PRNewsWire
- 3 months ago - Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases - PRNewsWire
- 4 months ago - Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions - PRNewsWire
- 5 months ago - Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 - PRNewsWire